Here is Matt Lowdon‘s weekly funding update covering news across medtech and biotech. CAR-T, longevity research, nerve stimulation and more. Congratulations to all involved.
➡️ Cancer immunotherapy company Liminatus Pharma, Inc has agreed to pay out shares worth $320m to buy CAR-T biotech InnocsAI.
➡️ Boston Scientific funnels $1.5B into MiRus®, with option to buy TAVR system
➡️ Medtronic has entered a deal to acquire SPR Therapeutics, company whose flagship product delivers short-term electrical nerve stimulation for chronic pain patients, for approximately $650m
➡️ With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
➡️ Lilly pens $202M deal for preclinical DNA delivery biotech Engage Biologics Inc. as M&A streak continues
➡️ Incyte is paying Genesis Molecular AI $80m upfront to expand use of its partner’s AI platform across a broader range of drug targets, continuing the biotech’s rapid embrace of AI in drug discovery and development.
➡️ TympaHealth Technologies Ltd secures £2m to scale ear and hearing health tech
➡️ Visium, the AI and data partner for enterprises in highly regulated industries, has announced the successful close of its first institutional funding round.
➡️ Retro Biosciences, the longevity startup backed by OpenAI CEO Sam Altman, has raised more money at a $1.8b valuation, it announced Friday.
➡️ LAUXERA CAPITAL PARTNERS has nearly doubled the size of its first funding drive with a €520m raise for health and medical technology companies.
➡️ BStartup adds medtech company DIGITAL ANATOMICS to its portfolio with a €420,000 financing round.
➡️ HCW Biologics raises $4m in private placement
➡️ Endologix LLC, a medtech that focuses on treatments for vascular diseases, expanded its offerings with the purchase of a mechanical thrombectomy system from Surmodics, Inc..
➡️ With $55m in fresh capital, Ulm-based NVision Quantum Technologies is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
➡️ Manchester-based biotech firm Imperagen, which builds an AI-driven enzyme engineering platform, has raised £5 million in a seed round
➡️ Macmillan Cancer Support, one of the UK’s largest charities supporting medical research and victims of cancer, has announced the launch of a venture capital firm to fund organisations developing medical innovations, Macmillan Ventures.